Agile 3+
Identification of advanced fibrosis in MASLD patients.
Learn more
Fast Target
Current MASH drug developments focus on patients with MASH at-risk of progression to cirrhosis or with compensated cirrhosis defined by Active Fibrotic MASH (MASH + NAS≥4 + F≥2).
Fast Construction
Fast combines FibroScan® examination results (LSM by VCTE™ & CAP™) with an easily accessible blood biomarker (AST) to help identify patients with active fibrotic-MASH, at the point-of-care, reducing invasive and costly procedures.
Fast Performance
Good to excellent performance in derivation cohort as well as in external validation cohorts from different clinical settings (MASLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia).
Several publications advocate the use of Fast.
Fast: tried and trusted
Improvements in Fast are consistent with amelioration of key histologic features of MASH, including both inflammation and fibrosis.
Fast score demonstrated good discrimination for fibrotic MASH in our cohort.
I believe that Fast is a key element for MASH clinical trials by enabling to decrease the screen failure rate and would further be of high interest to identify patients eligible to treatments.
All our solutions come with a dedicated support
From installation, to training and local support, we provide you with the highest quality of services.
Fast Score Calculator is a registered class 1 device (FDA). Fast Score Calculator is intended to compute the Fast score.
Fast Score Calculator was developed based on pools of cohorts and are published in peer-reviewed literature. It is taken from clinical literature and utilize proprietary FibroScan measurements in their execution. While these scores are about specific medical and health issues, Echosens does not represent them as substitutes for, or replacements of personalized medical advice, or to be used as the sole basis for making individualized medical or health-related decisions.
*MASLD/MASH is formerly knowed as NAFLD/NASH
